Microbot Medical shares surge 10.04% intraday after Roth Capital initiates Buy rating with $5.50 price target.

Microbot Medical surged 10.04% intraday after Roth Capital analyst Kyle Bauser initiated coverage with a Buy rating and a $5.50 price target. The firm highlighted the company’s Liberty system, a robotic platform for minimally invasive surgical procedures, as a catalyst for growth. While the company reported a wider-than-expected Q3 net loss of $3.6 million, the analyst’s positive outlook appears to have driven the intraday rally, overshadowing the earnings miss.